What Iolyx Therapeutics does

Iolyx Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunomodulatory therapies for ocular diseases at the intersection of immunology and ophthalmology. Its core technology platform centers on innovative pathways and tailored formulations designed for precise delivery to ocular tissues, with the explicit aim of treating inflammation at its source rather than symptomatically. The company's lead asset, ILYX-002, is a novel immunomodulatory therapeutic for autoimmune-associated dry eye disease that completed a 105-patient Phase 2 trial in 2025, demonstrating improved conjunctival staining versus comparator.

The company's pipeline extends beyond ILYX-002 to a horizontal portfolio spanning front-of-eye conditions (dry eye, ocular allergies, rosacea, uveitis) and back-of-eye indications (age-related macular degeneration, diabetic retinopathy, posterior uveitis), targeting conditions where current standard of care — steroids and immunosuppressants — have significant side effects and convenience limitations. Iolyx's go-to-market model relies on enterprise pharmaceutical partnerships rather than direct sales; its strategic December 2025 agreement with Laboratoires Théa provides up to $280 million in development and milestone funding plus royalties in exchange for Théa leading Phase 3 trials and regional marketing across global markets excluding Asia.

Iolyx is a privately held company headquartered in Burlingame, California, operating with a lean 1-10 employee footprint and venture-backed governance. Its customer segments are patient populations stratified by indication rather than enterprise buyers, with end-user revenue dependent on partner-led commercialization. The company recently closed a $15 million Series B financing led by Frazier Life Sciences, with board representation drawing from Stanford, Allergan, Pfizer, and Frazier, signaling institutional validation of its immuno-ophthalmology thesis.

Name

Iolyx Therapeutics

Legal name

Iolyx Therapeutics, Inc.

Website

https://iolyx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Iolyx Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunomodulatory therapies for ocular diseases, with lead asset ILYX-002 in Phase 3 for autoimmune dry eye disease under a strategic partnership with Laboratoires Théa covering global markets excluding Asia.

Ownership category

akta.pro rank

Product category

Ophthalmic Therapeutics

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industry

Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)

Keywords

• Immunomodulatory therapeutics
• Ocular disease therapies
• Biopharmaceutical development
• Dry eye treatments
• Ophthalmic drug development

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and Royalty Revenue: Iolyx generates revenue through licensing agreements and royalty streams from pharmaceutical partnerships. The company secured a strategic agreement with Laboratoires Théa valued at up to $280 million plus royalties for the development and commercialization of ILYX-002 in global markets excluding Asia.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Iolyx Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunomodulatory therapeutics for ocular diseases using innovative pathways and tailored formulations for precise delivery to relevant ocular tissues. Its lead asset ILYX-002 is advancing through Phase 3 development for autoimmune-associated dry eye disease, with a broader pipeline spanning front-of-eye (dry eye, ocular allergies, rosacea, uveitis) and back-of-eye (age-related macular degeneration, diabetic retinopathy, posterior uveitis) indications.

Product overview

Iolyx Therapeutics is a biopharmaceutical company developing a portfolio of targeted immunomodulatory therapeutics for ophthalmologic diseases. The company's core product is ILYX-002, currently in Phase 3 development for autoimmune-associated dry eye disease, with a broader pipeline targeting both front-of-eye conditions (dry eye, ocular allergies, rosacea, uveitis) and back-of-eye diseases (age-related macular degeneration, diabetic retinopathy, posterior uveitis). The company is advancing its pipeline through clinical trials, supported by a strategic partnership with Laboratoires Théa and $15 million Series B financing.

Differentiator

Problem solved

Functional benefit

Products and services

• ILYX-002

Quantifiable outcome

• Phase 2 trial with 105 patients showed improved conjunctival staining in dry eye disease

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Laboratoires ThéacoreStrategic or Co-development Partner · 3 December 2025Strategic agreement to develop and commercialize ILYX-002 for autoimmune-associated dry eye disease. Théa takes primary responsibility for Phase 3 trials and regional marketing. The agreement targets global markets excluding Asia, with potential funding of up to $280 million plus royalties. The partnership aims to accelerate development and bring targeted immuno-ophthalmology therapies to patients.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Aldeyra Therapeutics: Clinical-stage biotechnology company developing immunomodulatory therapies for ocular inflammatory diseases, including dry eye disease. Direct competitor to Iolyx in the targeted immunomodulation space for ocular surface inflammation.
• Kala Bio: Clinical-stage biopharmaceutical company developing therapeutics for eye diseases, including dry eye and other ocular surface conditions. Direct peer in ocular specialty pharma.
• Oyster Point Pharma: Acquired by Viatris, focused on developing therapeutics for dry eye disease, including Tyrvaya (varenicline nasal spray). Direct peer in the dry eye therapeutics category with a complementary mechanism.
• Apellis Pharmaceuticals: Commercial-stage biopharmaceutical company developing therapies for back-of-eye diseases including geographic atrophy (Syfovre) and other retinal inflammatory conditions. Peer in ocular immunomodulation targeting posterior segment indications.

Emerging players

• Mitotech S.A. Clinical-stage company developing novel ophthalmic drugs targeting mitochondrial dysfunction for dry eye disease. Comparable as an emerging ocular immunomodulation/mitochondria-focused peer.

Broad incumbents

• Regeneron Pharmaceuticals: Large biopharma with Eylea (aflibercept) franchise for back-of-eye retinal diseases including AMD and diabetic retinopathy. Broad incumbent comparator in ophthalmology inflammation.
• Bausch + Lomb: Diversified ophthalmology company with a broad portfolio across dry eye, cataract, and retinal indications, including Miebo for dry eye disease. Broad incumbent in ophthalmology therapeutics.
• Alcon: Global leader in eye care with broad portfolio spanning surgical, vision care, and pharmaceutical ophthalmology products including dry eye therapeutics. Broad incumbent benchmark.
• Novartis: Large pharmaceutical company with ophthalmology franchise including Xiidra for dry eye disease and Lucentis for retinal conditions. Broad incumbent comparator across both front-of-eye and back-of-eye markets.
• Horizon Therapeutics (Amgen): Acquired by Amgen; developed Tepezza for thyroid eye disease — a relevant precedent in immuno-ophthalmology and adjacent ocular inflammation therapeutic space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/people/IolyxTx/100082213912563/?mibextid=LQQJ4d
• LinkedInlinkedin.com/company/iolyx-therapeutics
• Instagraminstagram.com/iolyxtx

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iolyx Therapeutics